Noteworthy is the complete remission of CNS inflammation (patient 2), arthritis (patient 3), and ILD (patient 3) as well as the improvement of trachyonychia (patient 4) under baricitinib, whose effectiveness for STAT3-GOF-associated immune dysregulation has not been reported previously. This evidence concerns the gene STAT3 and interstitial lung disease.